Nocturnal activity with nighttime pergolide in Parkinson disease: A controlled study using actigraphy

Pergolide is a dopamine agonist that improves Parkinson disease but is associated with dose-dependent sleepiness. This study evaluates the effect of a nighttime dose of 1 mg of pergolide on actigraphic measures of sleep using a randomized, double-blind, placebo-controlled study design. The pergolide group ( n = 10) worsened in actigraphic measures of sleep efficiency and sleep fragmentation vs the placebo group ( n = 12). Side effects were more frequent in the pergolide group.